What is Mission Covid Suraksha? All you need to know
The government on Wednesday launched ‘Mission COVID Suraksha’, which will help the development process of approximately five to six Covid-19 vaccine candidates. Starting from the research and development part of the vaccines, the mission will help them in getting licence and will finally introduce them in the market. As several vaccines are in the final phase of trials, this mission will ensure that there is supply of enough doses of these vaccine shots, once they get approval.
1. Mission Covid Suraksha entails a grant of Rs 900 crore.
2. The department of biotechnology will get this grant.
3. The mission aims at providing end-to-end passage to vaccines — from preclinical stage to manufacturing.
4. The Centre had announced this package during the third stimulus.
5. The department is supporting the development of 10 vaccines. Five vaccine candidates are in human trials, including the Russian Vaccine Sputnik-V.
6. The aim of the project is to also establish clinical trial sites and strengthen the existing immunoassay laboratories, central laboratories and suitable facilities for animal studies, production facilities and other test facilities to support Covid-19 vaccine development, the DBT said.
Prime Minister Narendra Modi has recently met state chief ministers via video conferencing and asked the states to be prepared.
“It is not yet decided whether there will be one, two or three doses of vaccine. Their prices are also not decided. We don’t have answers to such questions right now as there are different people in the world making it. The corporate world is involved, there is competition among them, countries have their diplomatic interests, have to wait for WHO also,” Modi said.
Five vaccines are under different phases of clinical trial in India with the Serum Institute of India conducting phase-3 trial of the Oxford-Astrazeneca Covid-19 vaccine, while the indigenously developed Bharat Biotech and ICMR vaccine has already started the phase III clinical trial. Indigenously developed vaccine by Zydus Cadila has completed phase-2 clinical trial in the country. Dr Reddy’s Laboratories will soon start combined phase 2 and 3 clinical trials of the Russian Covid-19 vaccine Sputnik V in India.
Biological E. Ltd has started early phase 1 and 2 human trials of its Covid-19 vaccine candidate.
Enter your email to get our daily newsletter in your inbox
- For 2020-21, Delhi had pegged budgeted revenue receipts (excluding borrowings) at ₹55,309 crore. Revised estimates for the year will be mentioned in the upcoming budget (2021-22) and actual revenue receipts for the year will reflect in the budget after that.
- Court-appointed amicus curiae senior advocate Siddhartha Dave prepared a chart indicating unsatisfactory response from states as well with some proposing to achieve compliance of Court’s December 2, 2020 order by end of 2023.
- The judgment, which involved approximately ₹500 crore in tax revenue, will impact companies such as IBM India Ltd, Samsung Electronics Co Ltd, Hewlett Packard India, Mphasis Ltd, Sonata Software Ltd, and GE India, among others.
- The girl's family lodged a complaint three day after she went missing.
- Shubhendu Shubham, 23, a 2016-batch student of Patna’s Nalanda Medical College Hospital (NMCH), had taken the first shot of Covaxin in the first week of February, but tested positive for the viral infection later last month before he could take the second shot
- For the past 13 days, the Durga-Nag market at Dalgate in Srinagar has been desolate and locals and traders in grief
- TMC’s leader in the Rajya Sabha Derek O, Brien asked the Election Commission to stop the Prime Minister "from taking unfair advantages and undue publicity at tax payer’s cost during the conduct of elections".
- Ghulam Nabi Azad detractors and supporters in the Jammu and Kashmir Pradesh Committee accused each other of acting at the behest of the BJP.